BEAM™ combines EEG with automated neurocognitive tests and computes biomarkers referenced to our extensive normative database.
These analytics assist in differentiating dementia sub-types, quantifying severity of cognitive decline, tracking disease progression and assessing treatment efficacy.
BEAM™ biomarkers include
Neurodegenerative
Psychiatric
BEAM™ is
Imaging Modalities
HEALTHY AGING
NEURODEGENERATION
Healthy aging can be differentiated from neurodegenerative decline
™ – Sample Individual Patient ReportsPatient 1 – Healthy
Patient 2 – Alzheimer’s
BEAM™ is a fully mobile wireless device designed for use in any setting with rapid setup. New technicians can be trained and certified in a 4-hour session on-site.
64-year-old man – longitudinal study
Dx: amnestic MCI
Year 1 Patient scored 29 on MMSE
Year 2 Patient scored 25 on MMSE
MMSE score of 25 or higher is considered Normal
Although Patient’s Year 2 MMSE indicates Normal, his BEAM™ biosignature clearly shows he has moved from healthy to MCI. This patient should be monitoring his health and may be a candidate for newly available treatment.
